![Morning Star](https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/002/912/normal/Screen_Shot_2018-09-17_at_18.20.59.png?1537204915)
Rigel Announces Five Presentations at the EHA2024 Hybrid Congress
Morning Star,
Rigel Announces Five Presentations at the EHA2024 Hybrid Congress PR Newswire SOUTH SAN FRANCISCO, Calif., June 14, 2024 - Oral…
Rigel Announces Five Presentations at the EHA2024 Hybrid Congress PR Newswire SOUTH SAN FRANCISCO, Calif., June 14, 2024 - Oral…
- Oral presentation highlighting final five-year efficacy data from the registrational Phase 2 trial of REZLIDHIA® (olutasidenib…
- Oral presentation highlighting final five-year efficacy data from the registrational Phase 2 trial of REZLIDHIA® (olutasidenib…
- Oral presentation highlighting final five-year efficacy data from the registrational Phase 2 trial of REZLIDHIA® (olutasidenib…